6505-01-159-3648 ( NDC00029-4083-32 , TIGAN CAPSULES , TIGAN )
NSN Information
| NSN | FSC | NIIN | Item Name | INC |
|---|---|---|---|---|
| 6505-01-159-3648 | 6505 | 011593648 | TRIMETHOBENZAMIDE HYDROCHLORIDE | 3421 |
NSN Features
| MRC | Parameter | Characteristics |
|---|---|---|
| CQLS | CAPSULE CONTENT FORM | ANY ACCEPTABLE |
| CQCT | PRIMARY CONTAINER TYPE | BOTTLE |
| CYLZ | CAPSULE PRIMARY CONTAINER CONTENT QUANTITY | 500.000 |
| AKJA | ACTIVE MEDICAMENT MEDICINAL STRENGTH | 250.000 MILLIGRAMS TRIMETHOBENZAMIDE HYDROCHLORIDE ACTIVE INGREDIENT |
| AKJC | CAPSULE TYPE | ANY ACCEPTABLE |
Manufacturing Part Numbers (SKUs)
| Part SKU | Cage | Status | RNVC | RNCC | SADC | DAC | RNAAC |
|---|---|---|---|---|---|---|---|
| NDC00029-4083-32 | 04683 | A | 2 | 3 | 6 | 54 | |
| TIGAN CAPSULES | 04683 | A | 1 | 5 | 4 | KX | |
| TIGAN | 04683 | A | 1 | 5 | 6 | 54 |
Manufacturers
| Part SKU | Cage | Manufacturer | Type | Status |
|---|---|---|---|---|
| NDC00029-4083-32 | 04683 | KING PHARMACEUTICALS INC | A | A |
| TIGAN CAPSULES | 04683 | KING PHARMACEUTICALS INC | A | A |
| TIGAN | 04683 | KING PHARMACEUTICALS INC | A | A |
FLIS Identification
| PMIC | ADPE Code | CRITL Code | DEMIL Code | DEMIL INTG | NIIN Asgt | ESD | HMIC | ENAC | Schedule-B | INC |
|---|---|---|---|---|---|---|---|---|---|---|
| A | X | A | 1 | 08/06/1 | P | 3004909160 | 3421 |
FLIS Management
| MOE | REC Rep Code | Mgmt Ctl | USC | Phrase Code | Phrase Statement |
|---|---|---|---|---|---|
| DN | 9L----- | N | V | DISCONTINUED W/O REPLACEMENT |
Demilitarization Codes & Management
| DML | PMI | HMIC | ADP | CC | ESDC |
|---|---|---|---|---|---|
| A | A | P | X |
Miscellaneous Management
| MOE (S_A) | SOS | AAC | QUP | UI | SLC | CIIC | RC | MCC | SVC |
|---|---|---|---|---|---|---|---|---|---|
| DN | S9M | Y | 1 | BT | Q | U | 9L----- | N |
Management Control Army
| MATCAT 1 | MATCAT 2 | MATCAT 3 | MATCAT 4 5 | ARC |
|---|
Freight
| NMFC | NMFC SUB | UFC | HMC | LTL | LCL | WCC | TCC | SHC | ADC | ACC | ASH | NMF DESC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|